Nyxoah SA Ordinary Shares (NYXH) Stock Price

NYXHStock

$1.60−70.97%52W

Market Cap$162.94M

P/E—

PEG Ratio—

Div yield—

Beta1.05

NYXH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-73.32%

Price vs S&P 500 (4W)13.47%

VGM Score54.21

Book Value / Share (Quarterly)$0.96

P/TBV (Annual)4.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)48.11%

Cash Flow / Share (Quarterly)$-0.86

Price vs S&P 500 (YTD)-76.60%

Gross Margin (TTM)60.16%

Net Profit Margin (TTM)-367.79%

EPS (TTM)$-2.51

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-2.51

Revenue Growth (5Y)170.65%

EPS (Annual)$-2.74

ROI (Annual)-98.77%

Gross Margin (Annual)63.13%

Net Profit Margin (5Y Avg)-1491.46%

Cash / Share (Quarterly)$1.13

Revenue Growth QoQ (YoY)472.76%

ROA (Last FY)-76.04%

Revenue Growth TTM (YoY)299.17%

EBITD / Share (TTM)$-2.06

ROE (5Y Avg)-64.85%

Operating Margin (TTM)-310.76%

Cash Flow / Share (Annual)$-1.88

P/B Ratio1.68x

P/B Ratio (Quarterly)1.82x

Net Income / Employee (Annual)$-678,422

EV / Revenue (TTM)6.90x

Net Interest Coverage (TTM)-68.54x

ROA (TTM)-80.31%

EPS Incl Extra (Annual)$-2.74

Current Ratio (Annual)1.25x

Quick Ratio (Quarterly)2.31x

3-Month Avg Trading Volume0.20M

52-Week Price Return-70.97%

Revenue / Employee (TTM)$148,325

Tangible BV / Share (Quarterly)$0.41

P/S Ratio (Annual)13.96x

Asset Turnover (Annual)0.08x

52-Week High$7.38

Operating Margin (5Y Avg)-1461.02%

EPS Excl Extra (Annual)$-2.74

CapEx CAGR (5Y)7.45%

Tangible BV CAGR (5Y)77.76%

26-Week Price Return-61.39%

Quick Ratio (Annual)1.16x

13-Week Price Return-44.19%

Total Debt / Equity (Annual)0.86x

Current Ratio (Quarterly)2.38x

Enterprise Value$157.46M

Revenue / Share Growth (5Y)143.04%

Asset Turnover (TTM)0.15x

Book Value / Share Growth (5Y)-23.64%

Revenue / Employee (Annual)$75,496

Inventory Turnover (Annual)0.79x

Pretax Margin (Annual)-888.98%

Cash / Share (Annual)$1.29

3-Month Return Std Dev102.39%

Gross Margin (5Y Avg)63.57%

Net Income / Employee (TTM)$-722,954

ROE (Last FY)-183.36%

Net Interest Coverage (Annual)-13.75x

EPS Basic Excl Extra (Annual)$-2.74

Receivables Turnover (TTM)4.02x

Total Debt / Equity (Quarterly)0.72x

EPS Incl Extra (TTM)$-2.51

Receivables Turnover (Annual)2.21x

ROI (TTM)-101.49%

P/S Ratio (TTM)7.10x

Pretax Margin (5Y Avg)-1406.15%

Revenue / Share (Annual)$0.30

Tangible BV / Share (Annual)$1.95

Price vs S&P 500 (52W)-89.53%

Year-to-Date Return-64.75%

5-Day Price Return0.70%

EPS Normalized (Annual)$-2.74

ROA (5Y Avg)-37.16%

Net Profit Margin (Annual)-899.05%

Month-to-Date Return18.03%

Cash Flow / Share (TTM)$-1.85

EBITD / Share (Annual)$-2.40

Operating Margin (Annual)-833.18%

LT Debt / Equity (Annual)0.36x

ROI (5Y Avg)-44.45%

LT Debt / Equity (Quarterly)0.42x

EPS Basic Excl Extra (TTM)$-2.51

P/TBV (Quarterly)4.31x

P/B Ratio (Annual)3.58x

Inventory Turnover (TTM)1.91x

Pretax Margin (TTM)-358.84%

Book Value / Share (Annual)$1.32

Price vs S&P 500 (13W)-46.14%

Beta1.05x

Revenue / Share (TTM)$0.40

ROE (TTM)-175.29%

52-Week Low$1.32

vGradeD

gGradeA

mGradeD

vgmGradeC

NYXH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.47	-$0.67	-42.86%(-$0.20)
Q4 2025	Mar 19, 2026	-$0.64	-$0.68	-6.62%(-$0.05)
Q3 2025	Nov 13, 2025	-$0.65	-$0.73	-11.78%(-$0.08)
Q2 2025	Aug 18, 2025	-$0.66	-$0.64	+3.23%(+$0.02)

NYXH Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
NYXHNyxoah SA Ordinary Shares	D	A	D	$1.60
SYKStryker Corporation	C	B	C	$330.69
MMM3M Company	C	D	C	$174.34
BSXBoston Scientific Corp.	C	B	D	$46.84
BDXBecton, Dickinson and Co.	B	D	B	$189.52
MDLNMedline Inc. Class A common stock	C	D	C	$35.28
RMDResMed Inc.	C	B	B	$240.33
DXCMDexCom, Inc.	D	B	B	$90.82
WSTWest Pharmaceutical Services, Inc.	D	C	B	$337.47
SOLVSolventum Corporation	C	C	B	$91.12
BAXBaxter International Inc.	B	D	B	$26.13
PENPenumbra, Inc.	D	C	C	$321.68
GMEDGLOBUS MEDICAL INC	B	B	C	$82.97
GKOSGlaukos Corporation	F	A	A	$179.87
PODDInsulet Corporation	C	A	C	$145.13
TFXTeleflex Incorporated	B	F	B	$139.67
STVNStevanato Group S.p.A.	D	C	C	$21.03
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$20.10
MMSIMerit Medical Systems Inc	C	B	B	$90.49
HAEHaemonetics Corporation	C	C	A	$103.96
ICUIICU Medical Inc	C	D	B	$175.10
HTFLHeartflow, Inc. Common Stock	—	A	B	$47.78
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$120.25
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$47.57
ATRCAtriCure, Inc.	D	B	B	$48.54
UFPTUFP Technologies Inc	C	B	B	$300.05
NVCRNovoCure Limited Ordinary Shares	D	C	B	$17.82
LMATLeMaitre Vascular, Inc.	C	B	C	$80.45
INSPInspire Medical Systems, Inc.	B	B	B	$61.44
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$25.64
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.43
ATECAlphatec Holdings, Inc.	D	B	C	$9.44
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.64
IARTIntegra LifeSciences Holdings	B	D	B	$16.89
AORTArtivion, Inc.	C	C	C	$26.77
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$20.83
IRMDiRadimed Corporation	D	B	C	$87.07
BVSBioventus Inc. Class A Common Stock	B	C	A	$13.84
BBNXBeta Bionics, Inc. Common Stock	D	A	B	$19.72
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.42
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.21
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.48
MDXGMiMedx Group, Inc	C	D	C	$4.50
ANGOAngioDynamics, Inc.	C	D	A	$15.85
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$23.65
BWAYBrainsway Ltd. American Depositary Shares	F	A	B	$14.30
DCTHDelcath Systems Inc	D	B	A	$16.34
CERSCerus Corp	D	C	B	$2.65
TCMDTactile Systems Technology, Inc.	B	B	C	$23.16
NPCENeuropace, Inc. Common Stock	D	C	B	$14.41
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$15.55

About Nyxoah SA Ordinary Shares

Nyxoah SA develops and commercializes the Genio system, a CE-Mark validated bilateral neurostimulation therapy for moderate to severe Obstructive Sleep Apnea (OSA). The company addresses a substantial patient population, as OSA is associated with increased mortality risk and serious comorbidities including cardiovascular disease, depression, and stroke. Genio represents a novel treatment approach in a significant market opportunity for sleep-disordered breathing.